AbbVie’s Hep C Treatment Glecaprevir/Pibrentasvir Is Safe With Major HIV Regimens

In a small study with HCV/HIV-negative participants, G/P did not significantly interact with the drugs in Genvoya or Triumeq.

March 20, 2017

AbbVie’s experimental hepatitis C virus (HCV) regimen, glecaprevir/pibrentasvir, known as G/P, is safe for use with common antiretroviral regimens for HIV, aidsmap reports. A small study found that dose adjustments are not necessary when pairing G/P with Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) or Triumeq (dolutegravir/abacavir/lamivudine).

In February, AbbVie applied for U.S. Food and Drug Administration (FDA) approval of G/P, which the FDA has granted priority review status. A decision is expected in late June.

Presenting their findings at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, researchers conducted a Phase I study of 48 HCV/HIV-negative participants. The participants received different combinations of the study drugs over a 14- or 21-day period. They spent part of their time in the study taking either G/P or their assigned HIV regimen; the rest of the time, they took G/P and their assigned HIV regimen in combination.

Although the various HCV and HIV drugs did interact and change one another’s levels, the researchers concluded that these changes were not clinically significant and did not warrant dose adjustments.

To read the aidsmap article, click here.

To read the conference abstract, click here.

© 2026 Smart + Strong All Rights Reserved.